Tysabri Court Loss Gets Elan Into Another Fine Mess
Executive Summary
On July 21, Elan CEO Kelly Martin kicked off his company's half-year earnings call with lots of good news, something rare for the Irish biotech in the past few years
You may also be interested in...
Elan Moves Ahead With J&J Deal, But Does Biogen Really Approve?
Is it over? Elan Corp. and Johnson & Johnson said Sept. 17 they successfully closed their deal to share Alzheimer disease programs
Elan Moves Ahead With J&J Deal, But Does Biogen Really Approve?
Is it over? Elan Corp. and Johnson & Johnson said Sept. 17 they successfully closed their deal to share Alzheimer disease programs
Judge Says Elan's J&J Deal Violates Tysabri Contract, Handing Biogen A Victory
Biogen Idec's lawyers took heat all day Thursday from a federal judge, but in the end she ruled in their favor. Now, Elan has 23 days to fix the breach.